From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand

Kongsakon, Ronnachai; Lochid-amnuay, Surasit; Kapol, Nattiya; Pattanaprateep, Oraluck

doi:10.1016/j.vhri.2018.08.004

Cited by 11 publications

(23 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 22 EEs comparing adjuvant trastuzumab therapy with chemotherapy alone for HER2-positive EBC, published from year 2006 to 2018 (Table 1). As shown in Table 2, studies were mostly from high-income countries (HICs) [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43], while some [44][45][46][47][48][49] were from upper-middleincome countries (UMICs). About half [15,[28][29][30][31][32][33][34][35][36][37]44] were conducted and published as early as 2006 to 2009, which was within the early years of trastuzumab's market entry for HER2-positive early stage indication in 2006.…”

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

“…More than half [28][29][30][31][32][33][34][35][36][37][38][39][40]44] have been published even before 2013 when the WHO reviewed its inclusion in the WHO Essential Medicines List [50]. In terms of methodology, majority of the studies [30][31][32][36][37][38][39][40][41][42][43][44][45][46][47][48][49] adopted cost-utility analysis, while some [28,29,[33][34][35] used cost-effectiveness analysis. All except two studies [5,10] used decision analytic Markov modeling technique.…”

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

“…Health care payer or insurance perspective was the most commonly applied [28,[35][36][37][39][40][41]44,45]. Half of the studies modeled for lifetime horizon [30,34,37,39,[42][43][44][45][47][48][49], while others varied from 10 to 50 years. One-year cycle length was commonly applied [29,38,[41][42][43][44][45][46][47].…”

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

“…One-year cycle length was commonly applied [29,38,[41][42][43][44][45][46][47]. As regards to discounting, both costs [29][30][31][32][33][34][35][36][37][38]41,42,44,46,49] and outcomes [30][31][32][33]35,36,38,46,49] were mostly discounted at 3.0%. Finally, most studies handled uncertainty by conducting both one-way and probabilistic sensitivity analyses [30,31,[34][35][36][39][40][41][43][44][45][46]48,49].…”

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

“…The assessment of adequacy and transparency of reporting guided by the CHEERS checklist resulted in scores ranging from 61% by Neyt et al, 2006 [28] to 96% by Hall et al, 2011 [39] and Shiroiwa et al, 2008 [35]. The scores among HIC studies were from 61% [28] to 96% [35,39], while the scores among UMIC studies were from 83% [44,49] to 92% [45][46][47]. Less than half of the studies [29,30,32,35,39,42,[45][46][47][48] attained high scores of 90% or higher.…”

Section: Adequacy and Transparency Of Reportingmentioning

confidence: 99%

See 4 more Smart Citations

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Genuino

Gloria

Chaikledkaew

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: As the availability of new economic evaluations (EE) on adjuvant trastuzumab therapy for early-stage breast cancer (EBC) with HER2-positive since last search and other EEs missed warrant a more extensive review, this study aimed to systematically review EEs of adjuvant trastuzumab compared with chemotherapy alone for HER2-positive EBC. Area covered: The search was performed in February 2019 using MEDLINE and Scopus. Reviewers independently selected studies based on eligibility criteria, extracted data, assessed quality of reporting, and appraised quality of data sources. Expert opinion: 22 studies were included which were from high-income (HICs) and upper-middle income countries (UMICs). Incremental cost-effectiveness ratios (ICERs) from HICs were within their costeffectiveness thresholds and ranged from 6,018 to 78,929 USD per quality-adjusted life year (QALY) gained. ICERs from UMICs mostly exceeded their thresholds ranging from 3,526 to 174,901 USD per QALY gained. Evidence shows cost-effectiveness of trastuzumab for HER2-positive EBC in HICs. There were no methodological variations. The extent and adequacy of reporting were high. The quality of data sources was moderate to high. The quality of future EEs can be improved by enhancing the reporting quality, by using context-based data and real-world efficacy data, which would impact cost-effectiveness.

show abstract

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

Section: General Study Information and Methodological Variationsmentioning

confidence: 99%

Section: Adequacy and Transparency Of Reportingmentioning

confidence: 99%

See 3 more Smart Citations

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Genuino

Gloria

Chaikledkaew

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

Background. Understanding the cost of delivering breast cancer (BC) care in low-and middle-income countries (LMICs) is critical to guide effective care delivery strategies. This scoping review summarizes the scope of literature on the costs of BC care in LMICs and characterizes the methodological approaches of these economic evaluations. Materials and Methods. A systematic literature search was performed in five databases and gray literature up to March 2020. Studies were screened to identify original articles that included a cost outcome for BC diagnosis or treatment in an LMIC. Two independent reviewers assessed articles for eligibility. Data related to study characteristics and methodology were extracted. Study quality was assessed using the Drummond et al. checklist.Results. Ninety-one articles across 38 countries were included. The majority (73%) of studies were published between 2013 and 2020. Low-income countries (2%) and countries in Sub-Saharan Africa (9%) were grossly underrepresented. The majority of studies (60%) used a health care system perspective. Time horizon was not reported in 30 studies (33%). Of the 33 studies that estimated the cost of multiple steps in the BC care pathway, the majority (73%) were of high quality, but studies varied in their inclusion of nonmedical direct and indirect costs. Conclusion.There has been substantial growth in the number of BC economic evaluations in LMICs in the past decade, but there remain limited data from low-income countries, especially those in Sub-Saharan Africa. BC economic evaluations should be prioritized in these countries. Use of existing frameworks for economic evaluations may help achieve comparable, transparent costing analyses. The Oncologist 2021;26:1-12 Implications for Practice: There has been substantial growth in the number of breast cancer economic evaluations in lowand middle-income countries (LMICs) in the past decade, but there remain limited data from low-income countries. Breast cancer economic evaluations should be prioritized in low-income countries and in Sub-Saharan Africa. Researchers should strive to use and report a costing perspective and time horizon that captures all costs relevant to the study objective, including those such as direct nonmedical and indirect costs. Use of existing frameworks for economic evaluations in LMICs may help achieve comparable, transparent costing analyses in order to guide breast cancer control strategies.

show abstract

A systematic review of health state utility values in Thai cancer patients

Kangwanrattanakul

2022

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand

Cited by 11 publications

References 22 publications

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

A systematic review of health state utility values in Thai cancer patients

Contact Info

Product

Resources

About